Form 4 for KRYS Krystal Biotech, Inc.
Accepted 2024-05-22 00:00:00 ET · period of report 2024-05-20 · accession 0001532023-24-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-05-22 | 2024-05-20 | KRYS | Gangolli Julian S | Dir | S - Sale+OE | $164.14 | -20.0K | 0 | -100% | -$3.28M |
| D | 2024-05-22 | 2024-05-20 | KRYS | Gangolli Julian S | Dir | M - OptEx | $22.75 | +20.0K | 20.0K | New | +$455.0K |
| D | 2024-05-22 | 2024-05-20 | KRYS | Gangolli Julian S | Dir | M - OptEx | $0.00 | -20.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-20 | S | D | 10,930 | $163.71 | 9,070 | D | — | — | (F1) The transaction was executed in multiple trades ranging from $163.080 to $164.065. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 2 | Common | Common Stock | 2024-05-20 | S | D | 7,090 | $164.34 | 1,980 | D | — | — | (F2) The transaction was executed in multiple trades ranging from $164.085 to $164.850. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 3 | Common | Common Stock | 2024-05-20 | S | D | 1,980 | $165.76 | 0 | D | — | — | (F3) The transaction was executed in multiple trades ranging from $165.160 to $166.000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 4 | Common | Common Stock | 2024-05-20 | M | A | 20,000 | $22.75 | 20,000 | D | — | — | |
| 5 | Derivative | Stock Option (Right to Buy) | 2024-05-20 | M | D | 20,000 | $0.00 | 0 | D | $22.75 · — to 2029-03-01 | 20,000 Common Stock | (F4) The options were awarded on March 1, 2019 and vested monthly over a three-year period. |